Johnson & Johnson · product liability · mass tort litigation · bankruptcy
Has Johnson & Johnson been held liable for cancer claims over its talc products?
There is no single determination. As of 30 October 2026 some juries have returned verdicts against Johnson & Johnson in individual talc cases, while the company maintains its talc is safe and does not cause cancer. Courts dismissed three bankruptcy cases of J&J talc subsidiaries, in 2023 (twice) and on 31 March 2025. On 27 July 2026 J&J announced a proposed $5.5 billion settlement of about 76,000 remaining ovarian cancer claims, conditional on at least 95 percent participation, which is not a court finding or an admission of liability.
Last verified 30 October 2026. United States
The record at a glance
| What was alleged? | Tens of thousands of plaintiffs allege in state and federal lawsuits that Johnson & Johnson talc products, including baby powder, caused ovarian cancer or mesothelioma. Federal cases are consolidated in a multidistrict litigation before US District Judge Michael Shipp in New Jersey.1,2 |
|---|---|
| Who made the claim? | Individual plaintiffs in state and federal product liability lawsuits, |
| How did J&J respond? | J&J's position is that its talc is safe, does not contain asbestos and does not cause cancer. When announcing the proposed settlement its worldwide vice president of litigation, Erik Haas, said the company was confident it would ultimately have prevailed with further litigation, according to AP. J&J stopped selling talc based baby powder in the US in 2020 and worldwide in 2023, according to Reuters.1,2,3 (the subject's position) |
| Was there an official finding? | Federal courts dismissed the LTL Management Chapter 11 cases in 2023 and the Red River Talc case on 31 March 2025, so the talc claims were not resolved through bankruptcy.4,5,6 J&J has proposed but not yet completed a $5.5 billion settlement of remaining ovarian talc claims.1 |
| Was liability determined? | No, liability was not determined. No court has made an overall determination that J&J talc products cause cancer. Juries in individual cases have returned verdicts both for and against J&J. J&J's announcement of the proposed ovarian settlement contains no admission of liability and J&J continues to deny the claims. The earlier mesothelioma settlements are described by J&J only as settlements.1,3,6 |
| What changed later? | As of 30 October 2026 J&J's proposed $5.5 billion ovarian talc settlement announced on 27 July 2026 had not been reported as meeting its 95 percent participation condition, and MDL deadlines were reported as held in abeyance while participation is reported to the court.1,10 |
| When was this checked? | 30 October 2026 |
What was alleged?
Tens of thousands of plaintiffs allege in state and federal lawsuits that Johnson & Johnson talc products, including baby powder, caused ovarian cancer or mesothelioma. Federal cases are consolidated in a multidistrict litigation before US District Judge Michael Shipp in New Jersey.1,2
Made by Individual plaintiffs in state and federal product liability lawsuits on .
What did J&J say?
J&J's position is that its talc is safe, does not contain asbestos and does not cause cancer. When announcing the proposed settlement its worldwide vice president of litigation, Erik Haas, said the company was confident it would ultimately have prevailed with further litigation, according to AP. J&J stopped selling talc based baby powder in the US in 2020 and worldwide in 2023, according to Reuters.1,2,3
"Studies show talc is safe, does not contain asbestos and does not cause cancer."
Johnson & Johnson (company press release), 27 July 2026. This is the subject's own account, not a finding.
What do independent records show?
In re LTL Management LLC, No. 22-2003
US Court of Appeals for the Third Circuit, 30 January 2023
The court ordered dismissal of the first Chapter 11 case of LTL Management, the J&J subsidiary holding talc liabilities, holding it was not in financial distress when it filed and so the petition was not filed in good faith.4
In re LTL Management LLC, Nos. 23-2971 and 23-2972 (non-precedential)
US Court of Appeals for the Third Circuit, 25 July 2024
The court affirmed the bankruptcy court's dismissal of LTL's second Chapter 11 petition for lack of financial distress.5
In re Red River Talc LLC, No. 24-90505, ruling denying confirmation and dismissing the case
US Bankruptcy Court for the Southern District of Texas (Judge Christopher Lopez), 31 March 2025
The court refused to confirm the prepackaged plan and dismissed the case, citing voting irregularities, a channeling injunction protecting more than 700 non debtors, and nonconsensual third party releases contrary to Harrington v. Purdue Pharma, according to summaries by Hogan Lovells and HarrisMartin.6,7
Order granting motion to dismiss, Aronstein v. Kenvue, Inc., No. 3:24-cv-04665 (ECF No. 61, filed stamp 2 February 2026), with an accompanying memorandum opinion
US District Court for the District of New Jersey (Judge Michael Shipp), 29 January 2026
Granted the defendants' motion and dismissed the amended complaint without prejudice, with leave to file an amended complaint within 45 days. Reuters reported the ruling on 29 January 2026 and said the court found the plaintiffs' claimed injury from delay was hypothetical.2,8
Order to Show Cause, MDL No. 16-2738 (MAS) (RLS), ECF No. 45696, with a memorandum opinion of the same date
US District Court for the District of New Jersey, talc MDL No. 2738 (Magistrate Judge Rukhsanah L. Singh), 22 July 2026
Granted J&J's motion and ordered all plaintiffs to show cause within 120 days why their cases should not be dismissed with prejudice for failure to point to admissible expert opinion on specific causation. J&J then has 90 days to respond and the magistrate judge will issue a report and recommendation. J&J and AP said this followed the withdrawal of specific causation experts in two bellwether cases.1,3,9
Announcement of proposed resolution of ovarian talc litigation
Johnson & Johnson, 27 July 2026
J&J committed $5.5 billion, paid per claim, for about 76,000 remaining ovarian claims, conditional on at least 95 percent participation, with a first payment of no more than $3 billion in 2027. It said it had previously settled about 95 percent of filed mesothelioma lawsuits.1
Order holding deadlines in abeyance (reported)
US District Court for the District of New Jersey, talc MDL No. 2738, 28 August 2026
MDL deadlines, stayed on 29 July 2026, remained in abeyance, and negotiation counsel were directed to report to the court every two weeks on claimant participation in the settlement, according to MDL Update.10
What was established?
- Federal courts dismissed the LTL Management Chapter 11 cases in 2023 and the Red River Talc case on 31 March 2025, so the talc claims were not resolved through bankruptcy.4,5,6
- J&J has proposed but not yet completed a $5.5 billion settlement of remaining ovarian talc claims.1
Distinctions that matter here
- A jury verdict in an individual case is not a general scientific or legal finding and may be changed on appeal.
- A settlement without admission is not a finding of liability.
- Dismissal of the bankruptcy cases concerned the use of bankruptcy, not whether talc causes cancer.
Was liability determined?
No, liability was not determined. No court has made an overall determination that J&J talc products cause cancer. Juries in individual cases have returned verdicts both for and against J&J. J&J's announcement of the proposed ovarian settlement contains no admission of liability and J&J continues to deny the claims. The earlier mesothelioma settlements are described by J&J only as settlements.1,3,6
What remains unresolved?
- Whether the 95 percent participation threshold for the ovarian settlement will be met.
- How the MDL court will resolve the 22 July 2026 order to show cause on specific causation, which provides for plaintiff responses, a J&J reply and a report and recommendation by the magistrate judge. MDL deadlines were reported as held in abeyance from 29 July 2026.
- The status of remaining mesothelioma cases and appeals of individual verdicts.
- Whether the plaintiffs in Aronstein v. Kenvue filed an amended complaint after the dismissal without prejudice.
What is the current status?
As of 30 October 2026 J&J's proposed $5.5 billion ovarian talc settlement announced on 27 July 2026 had not been reported as meeting its 95 percent participation condition, and MDL deadlines were reported as held in abeyance while participation is reported to the court.1,10
As of 30 October 2026. No next proceeding is scheduled in the records we found.
Timeline
- Third Circuit orders dismissal of first LTL bankruptcy.4
- Third Circuit affirms dismissal of second LTL bankruptcy.5
- Red River Talc bankruptcy dismissed in Texas.6
- Judge Shipp dismisses, without prejudice and with leave to amend, a suit alleging the bankruptcy strategy was fraudulent.2,8
- MDL court orders all plaintiffs to show cause why their cases should not be dismissed for lack of admissible specific causation evidence.1,9
- J&J announces proposed $5.5 billion ovarian talc settlement.1
- MDL deadlines held in abeyance with biweekly participation reports, as reported.10
Sources
- Johnson & Johnson via SEC EDGAR, Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation (Exhibit 99.1 to Form 8-K), 27 July 2026 · document record Filing or formal statement by the subject
- Reuters (syndicated), US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy (Reuters), 29 January 2026 Independent reporting
- KSAT (Associated Press), Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight (AP), 28 July 2026 Independent reporting
- Justia (reproducing Third Circuit opinion), In re: LTL Management LLC, No. 22-2003 (3d Cir. 2023), 30 January 2023 · document record Court, legislation, official register or regulator record
- US Court of Appeals for the Third Circuit, In re LTL Management LLC, Nos. 23-2971 and 23-2972 (non-precedential opinion), 25 July 2024 · document record Court, legislation, official register or regulator record
- Hogan Lovells Cadwalader (law firm client publication), Johnson & Johnson's Red River Bankruptcy Strategy Sinks on Third-Party Release Issues, Voting Irregularities, 17 April 2025 Secondary commentary
- HarrisMartin, Bankruptcy Court Rejects Red River Talc's Prepackaged Reorganization Plan, Grants Motion to Dismiss, 31 March 2025 Independent reporting
- US District Court for the District of New Jersey (copy posted by ClassAction.org), Aronstein v. Kenvue, Inc., No. 3:24-cv-04665 (MAS) (RLS), Order granting Motion to Dismiss (ECF No. 61), 2 February 2026 · document record Court, legislation, official register or regulator record
- US District Court for the District of New Jersey (copy posted by Robert King Law Firm), In re Johnson & Johnson Talcum Powder Products Marketing, Sales Practices, and Products Liability Litigation, MDL No. 16-2738 (MAS) (RLS), Order to Show Cause (ECF No. 45696), 22 July 2026 · document record Court, legislation, official register or regulator record
- MDL Update, Johnson & Johnson Talcum Powder Products MDL 2738 (case tracker), 1 October 2026 Secondary commentary
Revision history
- 30 October 2026: Added the terms of the 22 July 2026 order to show cause and noted that a January 2026 dismissal was without prejudice with leave to amend.
- 30 October 2026: First published after source verification.
Related: Johnson & Johnson, product liability, mass tort litigation, bankruptcy, United States. To submit a document or request a correction, see right of reply.